Articles

Is the Federal Reserve suddenly open to cutting U.S. interest rates as early as July? That’s what Wall Street investors want to know when Fed Chair Jerome Powell testifies before Congress this week.

From trade wars to the threat of an actual kinetic war, seemingly nothing has managed to keep stocks down for long this year.

Inflation is the dry rot that eats away at your dream home while you’re busy making retirement plans.

U.S. inflation remained surprisingly muted through May, with limited impact from President Donald Trump’s tariffs. But U.S. airstrikes on Iran’s nuclear facilities over the weekend could contribute to pressures that may send price gains back to the highest levels in two years.

Mark Minervini shares what’s worked for him over his long trading career and talks about how to invest in the stock market now.

Trump Media, the parent of President Donald Trump’s social-media platform Truth Social, announced a $400 million stock-repurchase program, which could reduce the number of shares outstanding by 10%.

Tesla’s stock shot higher after Sunday’s launch of the EV maker’s eagerly anticipated — and recently delayed — robotaxi service in Austin, Texas.

Melius analysts expect more AI-chip sales as demand grows for running AI models and for AMD’s new offerings to attract hyperscaler and sovereign customers.

Nobody knows how badly the international oil market might be disrupted by Iran. But if you want to take advantage of the uncertainty, a screen encompassing debt levels and cash flow can limit your risk.

The cost of doing business for U.S. companies rose in June at the second-fastest pace in two and a half years, a pair of S&P surveys showed, reflecting ongoing inflation pressures tied to high Trump administration tariffs.

Sales of existing homes inched up slightly in May but remained depressed as buyers shied away from a housing market that features painfully high interest rates and home prices.

Hims & Hers Health Inc.’s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth-consultation company less than two months after it started.